China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids
Reuters
Sep 26
<a href="https://laohu8.com/S/CHSYF">China Medical System Holdings Ltd</a>. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids
**China Medical System Holdings Ltd. Announces NMPA Approval to Initiate Clinical Trials for Innovative Uterine Fibroid Drug** China Medical System Holdings Ltd. $(CMS)$ announced that its self-developed innovative drug, CMS-D002 Capsules, has received official approval from the National Medical Products Administration (NMPA) of China to begin clinical trials for the treatment of uterine fibroids. The approval, granted on 25 September 2025, allows CMS to proceed with evaluating the safety and efficacy of CMS-D002, a novel small molecule GnRH receptor antagonist. The company stated that this milestone will strengthen its position in the gynecological treatment field and aims to bring differentiated medication options to patients in China. The announcement did not mention the involvement of any other organizations in this regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.